

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44. DOI: 10.1056/NEJMoa1208953

SUPPLEMENTAL SECTION (for online publication only)

TABLE OF CONTENTS

Figure S1. Mean HCV RNA levels over time in genotype 1 patients	3
Figure S2. Mean hemoglobin levels over time in genotype 1 patients	4
Figure S3A. Mean on-treatment absolute neutrophil counts over time in genotype 2 and 3 patients during treatment	5
Figure S3B. Mean on-treatment absolute neutrophil counts over time in genotype 1 patients during treatment	6
Figure S4A. Mean on-treatment alanine aminotransferase levels over time in genotype 2 and 3 patients	7
Figure S4B. Mean on-treatment alanine aminotransferase levels over time in genotype 1 patients	8

Figure S1. Mean HCV RNA levels over time in genotype 1 patients




Figure S2. Mean hemoglobin levels over time in genotype 1 patients




Figure S3A. Mean on-treatment absolute neutrophil counts over time in genotype 2 and 3 patients during treatment




Figure S3B. Mean on-treatment absolute neutrophil counts over time in genotype 1 patients during treatment




Figure S4A. Mean on-treatment alanine aminotransferase levels over time in genotype 2 and 3 patients




Figure S4B. Mean on-treatment alanine aminotransferase levels over time in genotype 1 patients

